Cargando…
Accelerated development of malaria monoclonal antibodies
L9LS, a potent and safe antimalarial monoclonal antibody, demonstrated 88% protective efficacy against infection in a phase 1 trial in healthy adults.(1) These promising results are the first of many to usher in a potential new era of malaria prevention.
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9589116/ https://www.ncbi.nlm.nih.gov/pubmed/36260982 http://dx.doi.org/10.1016/j.xcrm.2022.100786 |